Q3 EPS Estimates for OPKO Health Lowered by Zacks Research

OPKO Health, Inc. (NASDAQ:OPK) – Zacks Research dropped their Q3 2026 earnings per share (EPS) estimates for OPKO Health in a note issued to investors on Thursday, March 19th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter, down from their previous forecast of ($0.06). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

A number of other research firms have also weighed in on OPK. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Barrington Research dropped their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Finally, Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.03.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.12 on Monday. The firm has a market capitalization of $850.16 million, a PE ratio of -3.73 and a beta of 1.50. OPKO Health has a 1 year low of $1.10 and a 1 year high of $1.83. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. The firm’s fifty day simple moving average is $1.23 and its 200 day simple moving average is $1.34.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. OPKO Health’s revenue for the quarter was down 19.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.01 earnings per share.

Hedge Funds Weigh In On OPKO Health

Several large investors have recently bought and sold shares of the stock. Caprock Group LLC bought a new stake in OPKO Health in the 3rd quarter valued at $26,000. Zacks Investment Management bought a new position in shares of OPKO Health during the 4th quarter worth about $27,000. StoneX Group Inc. acquired a new position in shares of OPKO Health during the fourth quarter valued at about $27,000. Swiss Life Asset Management Ltd acquired a new position in shares of OPKO Health during the third quarter valued at about $30,000. Finally, Savant Capital LLC bought a new stake in shares of OPKO Health in the third quarter valued at about $33,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Key OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his stake to 394,340 shares — insider buying often signals management confidence and can provide short‑term support. SEC Filing
• Positive Sentiment: Several institutional investors added or initiated positions in Q4 (e.g., World Investment Advisors, Virtu Financial, XTX Topco), indicating some institutional interest that can underpin the share base. MarketBeat Holdings Summary
• Neutral Sentiment: Analysts’ consensus remains a “Hold” rating on OPK (average price target near $2.03) — a mixed broker view that suggests limited near‑term conviction either way. Analyst Ratings Article
• Neutral Sentiment: Zacks published forward earnings commentary (including a FY2028 outlook) that highlights OPKO’s strengths (RAYALDEE sales, partnerships) but also calls out revenue decline and concentration risk — useful context for longer‑term investors. Zacks FY2028 Article
• Negative Sentiment: Zacks Research sharply cut near‑term and multi‑quarter EPS forecasts across Q3/Q4 2026–2027 and lowered FY2026/FY2027 estimates (many quarters now ~$(0.07)–$(0.08); FYs lowered toward ~$(0.29)). These downgrades meaningfully reduce profit expectations and are a primary driver of weaker investor sentiment today. Zacks Estimate Cuts (MarketBeat summary)
• Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50 (even while maintaining a constructive rating), which lowers the visible upside and can weigh on short‑term trading demand. Barrington PT Cut

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.